NapaJen Pharma Closes $12.4 Million Series C Financing

TOKYO and BURLINGAME, Calif., Jan. 9, 2019 -- (Healthcare Sales & Marketing Network) -- NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic ... Biopharmaceuticals, Venture Capital NapaJen Pharma, immunotherapeutic, oligonucleotide
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news